Cantor Fitzgerald has reiterated an Overweight recommendation on NewAmsterdam Pharma Co NV (NASDAQ:NAMS) and held its price target at $49.00 following the company's fourth-quarter earnings report. That target translates to about 42% potential upside from the current share price of $34.56; InvestingPro data cited by the firm suggests the stock may already be trading above its Fair Value.
The research house highlighted 2026 as an active year for NewAmsterdam, noting several clinical, regulatory, and commercial updates on the calendar. Investors were reminded that the company will next report results on March 4, which is just 13 days away from the present reference point.
A focal point for the company this year is the PREVAIL cardiovascular outcomes trial. Cantor Fitzgerald said the trial will begin a two-year blinded event analysis around April, with the subsequent event adjudication process expected to take roughly two months. The firm also anticipates that NewAmsterdam will provide an update on the timing for final PREVAIL topline data around mid-2026.
Separately, NewAmsterdam reported that the PREVAIL trial is progressing as expected, with event rates aligning with those observed in the Phase 3 BROADWAY trial. The company additionally announced that a European regulatory decision on obicetrapib, its cholesterol-lowering candidate, is anticipated in the second half of 2026.
Other advisory firms have adjusted their views on the company recently. Guggenheim raised its price target on NewAmsterdam to $45 while maintaining a Buy rating, citing an accelerated timeline for the EU launch of obicetrapib now expected in 2027 rather than 2029. Likewise, Leerink Partners lifted its price target to $55 and kept an Outperform rating, emphasizing what it called the under-appreciated potential of obicetrapib as a differentiated cardiovascular platform-in-a-product.
Cantor Fitzgerald's $49.00 target is unchanged from its prior assessment. The cluster of analyst actions and the company's public updates reflect continued confidence among several research teams in NewAmsterdam's strategic direction and the commercial prospects for obicetrapib, while also leaving room for investors to weigh valuation and timing risks tied to clinical and regulatory milestones.
Timeline and near-term events
- March 4 - Next scheduled earnings report from NewAmsterdam.
- Around April - PREVAIL will enter a two-year blinded event analysis.
- Following the analysis - Event adjudication is expected to take about two months.
- Mid-2026 - Anticipated update from the company on final PREVAIL topline data timing.
- Second half of 2026 - European regulatory decision expected for obicetrapib.
Market context
The combination of reiterated and raised price targets from multiple firms underscores attention on NewAmsterdam's clinical program and regulatory pathway. Analysts are projecting meaningful upside from current levels, even as third-party valuation data raises questions about whether the stock is already priced above intrinsic value.